ArticleViruses2014
Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop.
Article in Viruses, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A Review of Nonhuman Primate Models of Rift Valley Fever Virus Infection: Progress, Challenge Strains, and Future Directions.Pathogens (Basel, Switzerland) · 2024Review
- Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.NPJ vaccines · 2022Article
- Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates.Vaccines · 2022Article
- Adapting Simon's Two-Stage Design for Efficient Screening of Filovirus Vaccines in Non-Human Primates.Vaccines · 2022Article
- Article
- Review
- Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate.NPJ vaccines · 2020Article
- Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus.Human vaccines & immunotherapeutics · 2020Article
- Article
- Safeguarding against Ebola: Vaccines and therapeutics to be stockpiled for future outbreaks.PLoS neglected tropical diseases · 2018Article
- Article
- Development of a Lethal Intranasal Exposure Model of Ebola Virus in the Cynomolgus Macaque.Viruses · 2017Article
- Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.Scientific reports · 2017Article
- Ebola virus vaccines - reality or fiction?Expert review of vaccines · 2016Review
- Article
- Article
- Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.The Journal of infectious diseases · 2015Article
- Article
- Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.Nature · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On August 22-23, 2013, agencies within the United States Department of Defense (DoD) and the Department of Health and Human Services (HHS) sponsored the Filovirus Medical Countermeasures (MCMs) Workshop as an extension of the activities of the Filovirus Animal Non-clinical Group (FANG). The FANG is a federally-recognized multi-Agency group established in 2011 to coordinate and facilitate U.S. government (USG) efforts to develop filovirus MCMs. The workshop brought together government, academic and industry experts to consider the needs for filovirus MCMs and evaluate the status of the product development pipeline. This report summarizes speaker presentations and highlights progress and challenges remaining in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.